Clinical Trials Say that Rilonacept Significantly Reduces Gout Flares

Clinical trials are conducted in four different phases to decide the efficiency of the drug. Each stage of the clinical trial decides certain credentials of the drug before it runs into the market. The recent clinical trial running in Phase II shows positive results to treat the gout flares.  rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. The results of the clinical trials in the phase II stated that rilonacept is well tolerated with no serious infections or treatment-related serious adverse events reported. Unlike the placebo group that suffers from 33 flares, the active participants suffered only 6 flares. After a clinical trial conducted for 12 weeks, only 15 percent of the active group suffered from the infection when compared to the placebo participants